Hepatic MGAT2 expression is increased in MASLD patients, and knockout of Mgat2 reduces fat absorption and increases the secretion of GLP-1 and peptide YY (PYY), which are gut hormones that have beneficial effects on blood glucose and appetite remodeling [181, 182]. Here, PYY is linked to metabolic dysfunction-associated steatotic liver disease.